PROLOR Biotech to Present at 12th Annual Oppenheimer Israeli Conference

NES-ZIONA, Israel, May 10, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the 12th Annual Oppenheimer Israeli Conference, to be held at the David Intercontinental Hotel in Tel Aviv, Israel.  The presentation is scheduled for May 15, 2011 at 3:05 pm local time.

A copy of the company's updated corporate presentation, which includes an interim analysis of data from the company's Phase II trial of hGH-CTP, a long-acting version of human growth hormone, will be available starting on May 12, 2011 at the Investors section of PROLOR's website at www.prolor-biotech.com/?CategoryID=216

Shai Novik, President of PROLOR noted, "This is an exciting time for PROLOR.  The recent positive results from the interim analysis of our Phase ll trial showed that one injection of hGH-CTP has the potential to replace seven daily doses of commercial human growth hormone.  This sets the stage for us to complete the Phase II trial and advance preparations for our hGH-CTP Phase III registration trial planned for next year.  We welcome the opportunity to discuss our pipeline and recent progress with Israeli and US investors at this important conference."

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is in Phase II clinical development, and Factor IX, Factor VII, interferon beta and erythropoietin, which are in preclinical development, as well as an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis.  For more information, visit www.prolor-biotech.com.

PROLOR CONTACT:
Shai Novik, President
PROLOR Biotech, Inc.
Tel: +1 866 644-7811
Email: [email protected]

MEDIA CONTACT:
Barbara Lindheim
GendeLLindheim BioCom Partners
+1 212 918-4650
[email protected]

SOURCE PROLOR Biotech, Inc.

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.